Impact BioMedical Inc. has taken a significant step forward in its proposed merger with Zoar Ltd, as detailed in a recent SEC filing. The company announced the effectiveness of its Form F-4 registration statement on November 2, 2026. This merger is expected to enhance both companies' market positions in the pharmaceutical preparations industry.

The merger is particularly noteworthy as it comes at a time when the pharmaceutical sector is experiencing rapid changes and consolidation. By combining resources and expertise, Impact BioMedical and Zoar Ltd aim to create a more robust entity capable of competing effectively in the evolving market.

Background

Zoar Ltd, classified under the SIC code 2834 for Pharmaceutical Preparations, has recently undergone a name change from Dr Ashleys Ltd as of July 22, 2025. The company is incorporated in Hong Kong and operates primarily in the pharmaceutical sector. It trades under the ticker ZOAR, although it is not listed on any U.S. exchange.

Impact BioMedical Inc., also in the pharmaceutical preparations sector, is incorporated in Nevada. The company is actively pursuing growth opportunities, including this merger with Zoar Ltd, to expand its market reach and enhance its product offerings.

What the Filing Says

The SEC filing details that on November 2, 2026, Impact BioMedical released a press release regarding the effectiveness of its registration statement in connection with the merger with Zoar Ltd. The filing states, "The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended..." This indicates that the information is part of the ongoing regulatory process as the companies move toward finalizing the merger.

Impact

This merger could affect various stakeholders, including shareholders of both companies, employees, and customers in the pharmaceutical sector. The combination of Impact BioMedical and Zoar Ltd is expected to create a stronger entity that can better meet market demands and innovate within the industry.

What's Next

As the merger progresses, a definitive Proxy Statement/Prospectus will be mailed to Impact's stockholders for a vote on the business combination. This document will contain important information regarding the merger and is anticipated to be available shortly.

For more details, interested parties can access the filing through the SEC's website, with the accession number 0001493152-26-049726.